The influence of contraception on vaginal microflora can have a major impact on the risk of developing acute or recurrent vaginal infections, but also may influence the risk of acquiring sexually transmissible infections (STI) such as HIV. A cohort of 248 women presenting for levonorgestrel-releasing intrauterine system (LNG-IUS) insertion or reinsertion were stratified according to their current contraceptive method. Information concerning their menstrual pattern and data about the medical history were collected. The composition of their vaginal microflora was studied by detailed phase contrast microscopy of fresh vaginal fluid, and aerobic cultures were taken to detect enteric bacterial growth and fungal colonisation. LNG-IUS and progesterone-only-pill (POP) users had significantly lower blood loss (p < 0.001) than other women. Regardless of the type of contraception used, all women reported similar rates of symptomatic lower genital tract infection during the preceding year. Women using combined oral contraception (COC) and long-term LNG-IUS had the same bacterial composition of vaginal microflora as non-contraceptive users, even when infections were combined. Both hormonal and non-hormonal intrauterine device users had an increased tendency to have more vaginal colonisation with Candida. Women on POPs or subcutaneous implants had a tendency towards increased vaginal atrophy, but had a lower Candida carriage rate compared to IUCD users (LNG-IUS and Copper-IUCD, p = 0.037). Women with an increased risk of acquiring STIs or recurrent BV could benefit from LNG-IUS or COC due to a well-preserved vaginal bacterial flora. Women with a susceptibility for RVVC should prefer POPs, and avoid intrauterine contraception.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
None of the authors has any conflict of interest to disclose.
Ethical Committee University Hospital Leuven (Number S50518, Commission E330) and of General Hospital H Hart Tienen.
Read and signed by every patient before being considered for the study.
None of the authors declares any financial interest.
GD: Study design, patient recruitment, statistics, writing, editing; GB Study design, microscopy, editing; PH, DJ, BVB: patient recruitment, writing.
van de Wijgert JH, Kilmarx PH, Jones HE, Karon JM, Chaikummao S (2008) Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials. Contraception 77:122–129CrossRefPubMedGoogle Scholar
Tibaldi C, Cappello N, Latino MA, Masuelli G, Marini S, Benedetto C (2009) Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: risk factors and rates of occurrence. Clin Microbiol Infect 15:670–679CrossRefPubMedGoogle Scholar
Schwebke JR (2005) Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases. J Infect Dis 192:1315–1317CrossRefPubMedGoogle Scholar
Kumwenda NI, Kumwenda J, Kafulafula G, Makanani B, Taulo F, Nkhoma C et al (2008) HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS 19:339–341CrossRefPubMedGoogle Scholar
Pettifor A, Delany S, Kleinschmidt I, Miller WC, Atashili J, Rees H (2009) Use of injectable progestin contraception and risk of STI among South African women. Contraception 80:555–560CrossRefPubMedPubMedCentralGoogle Scholar
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E et al (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 12:19–26CrossRefPubMedGoogle Scholar
Donders GG (2007) Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 21:355–373CrossRefPubMedGoogle Scholar
Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (2002) Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 109:34–43CrossRefPubMedGoogle Scholar
Donders GG, Berger J, Heuninckx H, Bellen G, Cornelis A (2011) Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device. Contraception 83:352–356CrossRefPubMedGoogle Scholar
Neale R, Knight I, Keane F (2009) Do users of the intrauterine system (Mirena) have different genital symptoms and vaginal flora than users of the intrauterine contraceptive device? Int J STD AIDS 20:423–424CrossRefPubMedGoogle Scholar
Haukkamaa M, Stranden P, Jousimies-Somer H, Siitonen A (1986) Bacterial flora of the cervix in women using different methods of contraception. Am J Obstet Gynecol 154:520–524CrossRefPubMedGoogle Scholar
Keane FE, Ison CA, Taylor-Robinson D (1997) A longitudinal study of the vaginal flora over a menstrual cycle. Int J STD AIDS 8:489–494CrossRefPubMedGoogle Scholar
Hodoglugil NN, Aslan D, Bertan M (2000) Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. Contraception 61:359–364CrossRefPubMedGoogle Scholar
Ferraz do LR, Simoes JA, Bahamondes L, Camargo RP, Perrotti M, Monteiro I (2003) Follow-up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. Contraception 68:105–109CrossRefGoogle Scholar
Heffron R, Were E, Celum C, Mugo N, Ngure K, Kiarie J et al (2010) A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. Sex Transm Dis 37:621–628PubMedGoogle Scholar
Lessard T, Simoes JA, Discacciati MG, Hidalgo M, Bahamondes L (2008) Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-releasing intrauterine system (LNG-IUS). Contraception 77:30–33CrossRefPubMedGoogle Scholar
Toppozada M, Amer S, el-Ghazzawi E (1986) Effect of subdermal levonorgestrel contraceptive implants on vaginal candidiasis. Adv Contracept 2:117–122CrossRefPubMedGoogle Scholar
Spacek J, Buchta V, Jilek P, Forstl M (2007) Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 131:198–202CrossRefPubMedGoogle Scholar
Nohmi T, Abe S, Dobashi K, Tansho S, Yamaguchi H (1995) Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women’s vulnerability to vaginal candidiasis. Microbiol Immunol 39:405–409CrossRefPubMedGoogle Scholar
Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL (2004) Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 104:926–930CrossRefPubMedGoogle Scholar